JunHe Assisted Suzhou Zelgen Biopharmaceuticals Co., Ltd., m88 casino review First Unprofitable Application Enterprise on Sci-Tech Innovation Board in its Initial Public Offering and Listing

On January 23, 2020, Suzhou Zelgen Biopharmaceuticals Co., Ltd. ("Zelgen Biopharmaceuticals" or m88 casino review "Company") was listed on SSE STAR Market with m88 casino review stock code of 688266. JunHe acted as m88 casino review attorney of m88 casino review issuer. Zelgen Biopharmaceuticals issued 60 million new shares at an issue price of RMB 33.76 per share, and raised a total amount of RMB 2,025,600,000, with m88 casino review corresponding market value being RMB 8,102,400,000.

Zelgen Biopharmaceuticals is m88 casino review first innovative drug R & D enterprise to log on to m88 casino review Sci-Tech Innovation Board (to which m88 casino review fifth set of standards for m88 casino review board are applicable), as well as m88 casino review first enterprise in m88 casino review history of m88 casino review A-share capital market to successfully achieve initial public offering and listing of shares without any operating income or profit. Before m88 casino review launch of m88 casino review Sci-Tech Innovation Board, due to m88 casino review requirements of m88 casino review issuer's net profit indicators as specified by m88 casino review traditional A-share listing conditions, innovative drug R & D enterprises with advanced technology but still in m88 casino review R & D stage can only choose to list on overseas stock exchanges such as m88 casino review Hong Kong Stock Exchange and m88 casino review NASDAQ. With m88 casino review successful listing of Zelgen Biopharmaceuticals, Sci-Tech Innovation Board has achieved a breakthrough of "zero" in m88 casino review listing of enterprises yet to make a profit (to which m88 casino review fifth set of standards for m88 casino review board are applicable) and become an important milestone in m88 casino review development of China's capital market.

Founded in 2009, Zelgen Biopharmaceuticals is an innovative chemical and biotechnology drug R & D enterprises specializing in m88 casino review treatment of oncology, hematology and hepatobiliary disease. m88 casino review Company is committed to research and development of innovative drugs that are safe, effective, affordable, and have global proprietary intellectual property rights, so as to meet m88 casino review huge demand of m88 casino reviewrapeutic markets both home and abroad. m88 casino review Company has independently developed a series of product line for small molecule new drug and bispecific/tri-specific antibody with patent protection. This has enabled company to build-up a strong pipeline covering such treatment areas as liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases.

As m88 casino review attorney of m88 casino review issuer, JunHe participated in m88 casino review whole process of listing preparation, and assisted m88 casino review Company in completing major legal matters such as acquisition of m88 casino review controlling stake in a US company, private equity financing before listing, shareholding reform, development of an employee stock ownership plan, FTO patent investigation, state-owned shareholder identity management, resolution of potential conflicts of interest between m88 casino review Company and its actual controller's related parties, etc. JunHe team with consistent efficiency, diligence, stable work style, carefulness, professional service attitude, has been unanimously recognized by m88 casino review Company and om88 casino reviewr intermediary agencies.

m88 casino review leading partner of this Project is SHI Tiejun and.